Canaccord lowered the firm’s price target on AngioDynamics to $17 from $19 and keeps a Buy rating on the shares. The firm noted the company’s guidance cut given its Q2 miss and continued thrombectomy woes. Canacord said its valuation keeps them engaged as it remains cheap on a sum-of-the-parts basis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANGO:
- AngioDynamics down 10% at $7.00 after Q2 revenue miss, FY24 guidance cut
- AngioDynamics cuts FY24 EPS view to (42c) to (35c) from (34c) to (28c)
- AngioDynamics reports Q2 EPS (5c), consensus (7c)
- Options Volatility and Implied Earnings Moves Today, January 05, 2024
- Options Volatility and Implied Earnings Moves This Week, January 03 – January 05, 2024
